Seeking alternative biological therapies: The future of targeted molecular treatment

Oral Oncology

Volumn 45, Issue 4-5, 2009, Pages 447-453

  Lorch, Jochen H ^a   Posner, Marshall R ^a   Wirth, Lori J ^a   Haddad, Robert I ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 4 AMINO 5 (3 BENZYLOXYPHENYL) 7 [3 (1 PYRROLIDINYLMETHYL)CYCLOBUTYL] 7H PYRROLO[2,3 D]PYRIMIDINE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AFLIBERCEPT; AMG 479; AMG 655; BEVACIZUMAB; BORTEZOMIB; CETUXIMAB; EM 164; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; LAPATINIB; LONAFARNIB; MATUZUMAB; MONOCLONAL ANTIBODY; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PANITUMUMAB; RAF PROTEIN; RAS PROTEIN; SCATTER FACTOR RECEPTOR; SORAFENIB; SUNITINIB; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

APOPTOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DISEASE COURSE; DRUG TARGETING; HEAD AND NECK CANCER; HUMAN; MOLECULAR THERAPY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; APOPTOSIS; BIOLOGICAL THERAPY; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; DRUG DELIVERY SYSTEMS; HEAD AND NECK NEOPLASMS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PHOSPHOTRANSFERASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, SOMATOMEDIN; SIGNAL TRANSDUCTION;

EID: 67349177751     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2008.08.009     Document Type: Review

References (48)

1. Forastiere A.A., and Burtness B.A. Epidermal growth factor receptor inhibition in head and neck cancer-more insights, but more questions. J Clin Oncol 25 (2007) 2152-2155
2. Grandis J.R., and Tweardy D.J. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53 (1993) 3579-3584
3. Vermorken J.B., Trigo J., Hitt R., et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25 (2007) 2171-2177
4. Vermorken JB, Mesia R, Vega V, et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum-based therapy - results of a randomized phase III (extreme) study. Proc Am Soc Clin Oncol, 2007 [abstract #6091].
5. Kies M.S., Ghebremichael M.S., Katz T.L., Herbst R.S., Youssoufian H., and Burtness B. EGF-R expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 25 (2007) [abstract #6024]
6. O'Neil B.H., Allen R., Spigel D.R., et al. High incidence of cetuximab-related infusion reactions in tennessee and North Carolina and the association with atopic history. J Clin Oncol 25 (2007) 3644-3648
7. Chung C.H., Mirakhur B., Chan E., et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1, 3-galactose. N Engl J Med 358 (2008) 1109-1117
8. Hitt R., Irigoyen A., Nuñez J., et al. Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish head and neck cancer group (TTCC). Proc Am Soc Clin Oncol 25 (2007) [abstract #6012]
9. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
10. Curran D., Giralt J., Harari P.M., et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 25 (2007) 2191-2197
11. Cohen E.E., Kane M.A., List M.A., et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 11 (2005) 8418-8424
12. Soulieres D., Senzer N.N., Vokes E.E., Hidalgo M., Agarwala S.S., and Siu L.L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22 (2004) 77-85
13. Agulnik M., da Cunha Santos G., Hedley D., et al. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol 25 (2007) 2184-2190
14. Kim E.S., Kies M.S., Glisson B.S., et al. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer. Proc Am Soc Clin Oncol 25 (2007) [abstract #6013]
15. Wirth L.J., Haddad R.I., Lindeman N.I., et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 23 (2005) 6976-6981
16. Abidoye O.O., Cohen E.E., Wong S.M., et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 24 (2006) [abstract #]
17. Lai S.Y., Lui V.W., Koppikar P.J., et al. Intratumoral epidermal growth factor receptor (EGFR) antisense (AS) DNA in recurrent squamous cell carcinoma of the head and neck (SCCHN): A phase I trial. Proc Am Soc Clinic Oncol 25 (2007) [abstract 6009]
18. Scharf J.G., Dombrowski F., and Ramadori G. The IGF axis and hepatocarcinogenesis. Mol Pathol 54 (2001) 138-144
19. Grothey A., Voigt W., Schober C., Muller T., Dempke W., and Schmoll H.J. The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J Cancer Res Clin Oncol 125 (1999) 166-173
20. Wu X., Zhao H., Do K.-A., et al. Serum levels of insulin growth factor (IGF-I) and IGF-binding protein predict risk of second primary tumors in patients with head and neck cancer. Clin Cancer Res 10 (2004) 3988-3995
21. Thomas C.Y., Jameson M., and Beckler A. Interaction of EGF-R and IGF-1R signals to modulate the anti-proliferative and biochemical responses of head and neck squamous cancer (HNSCC) cells to EGF-R inhibitors. J Clin Oncol (Meeting Abstracts) 25 (2007) 6045
22. Lo Muzio L., Farina A., Rubini C., et al. Effect of c-met expression on survival in head and neck squamous cell carcinoma. Tumor Biol 27 (2006) 115-121
23. Zeng Q., Chen S., You Z., et al. Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NF-kappa B. J Biol Chem (2002) M201598200
24. Ma P.C., Tretiakova M.S., Jagadeeswaran R., et al. Role of c-MET in lung cancer, malignant mesothelioma, and head and neck cancer. J Clin Oncol (Meeting Abstracts) 22 (2004) 9539
25. Dong G., Lee T.L., Yeh N.T., Geoghegan J., Waes C.V., and Chen Z. Metastatic squamous cell carcinoma cells that overexpress c-Met exhibit enhanced angiogenesis factor expression, scattering and metastasis in response to hepatocyte growth factor. Oncogene 23 (2004) 6199-6208
26. Hoa M., Davis S.L., Ames S.J., and Spanjaard R.A. Amplification of wild-type K-ras promotes growth of head and neck squamous cell carcinoma. Cancer Res 62 (2002) 7154-7156
27. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26 (2008) 1626-1634
28. Chun K.H., Lee H.Y., Hassan K., Khuri F., Hong W.K., and Lotan R. Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. Cancer Res 63 (2003) 4796-4800
29. Yang C.H., Kies M.S., Glisson B., et al. A phase II study of lonafarnib (SCH66336) in patients with chemo-refractory advanced head and neck squamous cell carcinoma (HNSCC). J Clin Oncol (Meeting Abstracts) 23 (2005) 5565
30. Beeram M., Patnaik A., and Rowinsky E.K. Raf: A strategic target for therapeutic development against cancer. J Clin Oncol 23 (2005) 6771-6790
31. Weber A., Langhanki L., Sommerer F., Markwarth A., Wittekind C., and Tannapfel A. Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene 22 (2003) 4757-4759
32. Williamson S.K., Moon J., Huang C.H., Guaglianone P., Wolf G.T., and Urba S.G. A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): A southwest oncology group (SWOG) trial. Proc Am Soc Clin Oncol 25 (2007) [abstract #6044]
33. Elser C., Siu L.L., Winquist E., et al. Phase II Trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 25 (2007) 3766-3773
34. Rini B.I. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res 14 (2008) 1286-1290
35. Sorrells D.L., Ghali G.E., Meschonat C., et al. Competitive PCR to detect eIF4E gene amplification in head and neck cancer. Head Neck 21 (1999) 60-65
36. Sorrells D.L., Meschonat C., Black D., and Li B.D. Pattern of amplification and overexpression of the eukaryotic initiation factor 4E gene in solid tumor. J Surg Res 85 (1999) 37-42
37. Haydon M.S., Googe J.D., Sorrells D.S., Ghali G.E., and Li B.D. Progression of eIF4e gene amplification and overexpression in benign and malignant tumors of the head and neck. Cancer 88 (2000) 2803-2810
38. Neshat M.S., Mellinghoff I.K., Tran C., et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci 98 (2001) 10314-10319
39. Jimeno A., Kulesza P., Wheelhouse J., et al. Dual EGF-R and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer 96 (2007) 952-959
40. Seiwert T.Y., Davis D.W., Yan D., et al. PKDR/KDR ratio predicts response in a phase I/II pharmacodynamic study of erlotinib and bevacizumab for recurrent or metastatic head and neck cancer (HNC). Proc Am Soc Clin Oncol 25 (2007) [abstract #6021]
41. Gordon M.S., Margolin K., Talpaz M., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19 (2001) 843-850
42. Patel V., Lahusen T., Leethanakul C., et al. Anti-tumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27KIP1. Clin Cancer Res 8 (2002) 3549-3560
43. Rossi M, Oberst A, Sayan AE, Salomoni P. Proteasome inhibitors in cancer therapy: death by indigestion. Cell Death Differ 12:1255-7.
44. Lorch J.H., Thomas T.O., and Schmoll H.J. Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. Cancer Res 67 (2007) 727-734
45. Carlo-Stella C., Lavazza C., Locatelli A., Vigano L., Gianni A.M., and Gianni L. Targeting TRAIL agonistic receptors for cancer therapy. Clin Cancer Res 13 (2007) 2313-2317
46. Teng M.S., Brandwein-Gensler M.S., Teixeira M.S., Martignetti J.A., and Duffey D.C. A study of TRAIL receptors in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 131 (2005) 407-412
47. Nemunaitis J., Ganly I., Khuri F., et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 60 (2000) 6359-6366
48. Rudin C.M., Cohen E.E., Papadimitrakopoulou V.A., et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 21 (2003) 4546-4552